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Abstract  29 
Background; IBD patients with acute severe colitis face systemic anti-TNF biologic rescue therapy or 30 
colectomy, if treatment with intravenous steroids fail. Interleukin (IL)-27 is a cytokine with an 31 
immunosuppressive role in adaptive immune responses. However, the IL-27 receptor complex is 32 
also expressed on innate immune cells, and there is evidence that IL-27 can impact the function 33 
of innate cell subsets, although this particular functionality in vivo is not understood. Our aim was 34 
to define the efficacy of IL -27 in acute severe colitis and characterize novel IL -27 driven mechanisms of 35 
immunosuppression in the colonic mucosa.  36 
Methods; We assessed oral delivery of Lactococcus lactis expressing an IL -27 hyperkine on the innate 37 
immune response in vivo in a genetically intact, non-infective acute murine colitis model induced by 38 
intra-rectal instillation of 2,4,6-Trinitrobenzenesulfonic acid in SJL/J mice. 39 
Results; IL -27 attenuates acute severe colitis through reduction of colonic mucosal neutrophil infiltrate 40 
associated with a decreased CXC chemokine gradient. This suppression was T cell-indep ndent and IL -41 
10-dependent, initially featuring enhanced mucosal IL -10. IL -27 was associated with a reduction in 42 
colonic pro-inflammatory cytokines and induced a multifocal strong positive nuclear expression of 43 
phosphorylated STAT-1 in mucosal epithelial cells.  44 
Conclusion; We have defined novel mechanisms of IL-27 immunosuppression towards colonic innate 45 
immune responses in vivo. Mucosal delivery of IL -27 has translational potential as a novel therapeutic for 46 
IBD and is a future mucosal directed rescue therapy in acute severe inflammatory bowel disease.  47 
 48 
Keywords; interleukin-27, cytokine, IBD, colitis  49 
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Introduction 50 
Inflammatory bowel disease is a progressive relapsing remitting inflammation of the 51 
gastrointestinal tract 1 and is increasing in incidence globally 2. Biologic therapy has revolutionized 52 
patient management 3, 4. Despite this and the use of other immunosuppressant drugs, there remains a 53 
significant cohort of patients with refractory or relapsing disease, or those that cannot tolerate available 54 
treatments. The systemic nature of current immunosuppressant therapies is associated with an appreciable 55 
risk of significant adverse events and carries a financial burden. Novel, saf r and more affordable 56 
treatment strategies are required for maintenance therapies.  57 
Acute severe colitis requires hospital admission for intravenous steroid therapy and close 58 
monitoring, due to potential life threatening complications such as perforation and toxic dilatation 5-7. Up 59 
to 15% of patients present with acute severe disease. Clinical and laboratory severity markers predict the 60 
need for emergent colectomy and 85% of patients with >8 stools/day or 3-8 stools/day and raised CRP 61 
>45mg/L on day 3 need urgent consideration of escalated medical therapy with rescue infliximab anti-62 
TNF biologic therapy or intravenous ciclosporin, or surgery. If medical therapy fails by day 7 or life 63 
threatening complications occur, emergency colectomy with ileostomy is required as a life aving 64 
treatment. This clinical need for life saving and life changing surgery unfolds rapidly and can be 65 
associated with post-operative psychosocial morbidity, especially in adolescent and young adult patients66 
8-10.There is a need for novel rescue therapies for the treatment of acute severe colitis. 67 
We previously demonstrated that oral delivery of Lactococcus lactis (L. lactis) expressing an IL -68 
27 hyperkine (LL-IL -27), composed of both EBI3 and p28 subunits, a linker molecule and secretary 69 
peptide, is immunosuppressive in murine chronic enterocolitis induced by CD4+CD45Rbhi T cell transfer 70 
11. In this T cell driven colitis model, representing adaptive immune responses, LL-IL -27 led to significant 71 
histological improvement and survival advantage, through induction of IL -10 derived from intra-epithelial 72 
mucosal T cells. We also described an immunosuppressive action on acute DSS colitis 11, although the 73 
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mechanism was not explored. We then hypothesized that IL-27 may exert an immunosuppressive rol  in 74 
innate immune responses.  75 
IL-27, a heterodimeric cytokine composed of EBI3 and p28 subunits, is secreted from 76 
antigen presenting cells and signals via a heterodimeric receptor complex composed of the 77 
widely expressed Gp130, and the specific IL-27Rα 12-14. IL-27 was initially considered pro-78 
inflammatory through promotion of Th1 responses 15. There is now appreciation that IL-27 has a 79 
wide functional repertoire, including profound anti-inflammatory effects through promotion of 80 
IL-10 secreting Tr1 regulatory T cells and inhibition of Th2 and Th17 responses 12-14. 81 
Knowledge of IL-27 functionality has largely come from T cell biology, and its role in the 82 
adaptive immune response is well described 12-14. However, the IL-27 receptor complex is also 83 
expressed on other immune cell types, including granulocytes 16 and macrophages 17, indicating 84 
that the functional capabilities of IL27 may be even wider and in particular IL27 may play a role 85 
in mediating innate immunity. Indeed, IL-27 can impact the function of innate cell subsets, 86 
including macrophages 18, neutrophils 16, 19, and dendritic cells 20-22. It has been shown that IL-27 87 
influences innate responses to bacterial challenge in the context of systemic sepsis in genetic 88 
manipulation models such as IL-27Rα knock-out murine strains. 23,24. To date, there is no report 89 
on the immunosuppressive mechanism of IL27 in acute inflammation of the colon driven by 90 
innate cells in a genetically intact, non-infective environment. 91 
Here, by demonstrating an immunosuppressive effect of IL -27 on the innate, rather than adaptive, 92 
immune response in vivo in a genetically intact, non-infective acute murine colitis model induced by 93 
intra-rectal instillation of 2,4,6-Trinitrobenzenesulfonic acid (TNBS), we offer novel mechanistic insights 94 
into the biology of IL-27 in vivo. Our data highlights the immunosuppressive role of IL-27 in innate 95 
immune responses offering translational potential as a novel rescue therapy in acute severe colitis.  96 
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Materials and Methods 98 
Study approval - Animal experiments were conducted under approved protocols by the NCI Animal 99 
Care and Use Committee, in keeping with federal regulations governing care and use of animals in 100 
biomedical research. Frederick National Laboratory is accredited by AAALAC International and follows 101 
the Public Health Service Policy for the Care and Use of Laboratory Animals. Animal care was provided 102 
in accordance with the procedures outlined in the “Guide for Care and Use of Laboratory Animals” 103 
(National Research Council; 2011; National Academies Press; Washington, D.C.). 104 
Animals – Experiments were performed on 6-10 week old male SJL/J, B6 Rag-/- (01BJ2 - B6.129S7-105 
Rag1), and B6 IL -10-/- (01IL6 - IL -10 GFP/C) mice, maintained within the NCI-Frederick animal facility. 106 
Mice were fed normal chow, had free access to water and exposure to a 12 hourly light/dark cycle.  107 
Acute colitis induction –100 µl TNBS (Sigma, ~1M in H2O, stored at -20oC, 92823) in 45% ethanol 108 
vehicle was administered intra-rectally to isoflurane anaesthetized mice with a 3cm flexible catheter. The 109 
administered dose was optimized within our facility and dependent on the sensitivity of the mouse strain; 110 
2mg for SJL/J, 4mg for B6/Rag-/- and 6mg for B6/IL -10-/-. The mice were held vertically for > 30secs post 111 
instillation to ensure retention. Mice were given supportive care (wet food/ice chips/heat pad) throughout 112 
the protocol. Prior to colitis induction, mice were fasted to solid food overnight and given access to 5% 113 
sucrose water.  114 
Bacterial handling and administration – Lactococcus lactis (L. lactis) expressing IL -27 (LL-IL -27) and 115 
L. lactis empty vector control (LL-C) were prepared as described previously 11. Briefly, L. lactis strain 116 
MG1363 was used for bacterial preparations. A bacterial research bank was prepared and IL -27 secretion 117 
confirmed by IL -27p28 ELISA (R&D systems, M2728) before storage in 50% glycerol at -80oC. For oral 118 
administration, stock bacteria were cultured 1:1000 in Difco M17 broth (BD Biosciences,218561) 119 
supplemented with 0.5% glucose and 5mg/ml erythromycin (Sigma, E5389) (GM17E) at 30oC for 16 120 
hours. The bacteria were harvested by centrifugation and resuspended in buffered M9 salt media. Each 121 
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mouse was administered 100 µl of this bacterial suspension by oral gavage at 24 hour intervals within the 122 
treatment protocol, commencing on the day of colitis induction following recovery from anesthesia.  123 
Clinical assessment of colitis activity – Disease activity index was assessed daily as previously reported 124 
11. This is a composite score (maximum 12) of three parameters: weight loss from baseline (≤1% 0, 125 
1<≤5% 1, 5<≤10% 2, 10<≤20% 3, >20% 4), consistency of stool (normal pellets 0, soft-semi formed 2, 126 
diarrhea 4) and presence of fecal blood (none 0, occult blood positive 2, overt blood 4). Macroscopic 127 
colitis score was assessed by colon weight (mg) and length (cm) immediately after harvest. Histological 128 
colitis score (maximum 14) was reported by a veterinary pathologist (MRA) based on multiple 129 
parameters: severity of inflammatory cell infiltrate (none 0, mild 1, moderate 2, severe 3), goblet cell 130 
depletion (none 0, mild 1, moderate 2, severe 3), crypt hyperplasia (none 0, mild 1, moderate 2, sever3), 131 
degree of ulceration of epithelium, (none 0, erosion 1, mild 2, moderate 3, severe 4 ulceration), presence 132 
(1) or absence (0) of granulomas. 133 
Measurement of systemic inflammatory response – Blood was collected on day 2 post TNBS 134 
instillation in a serum separator tube, centrifuged and the supernatant stored at -80oC for analysis. Serum 135 
C-reactive protein (CRP) was measured using ELISA kit (Life Diagnostics Inc, 2210-1) as per 136 
instructions.  137 
Gene expression – RNA was extracted from cells or snap frozen distal colon tissue with the RNeasy mini 138 
kit (Qiagen, 74104) as per instructions. Quality and yield were assessed by Nanodrop spectrophotometry. 139 
cDNA was synthesized using the QuantiTect reverse transcription kit (Qiagen, 205310) with inclusive 140 
genomic DNA wipeout buffer. Further details of gene expression assays are available in the 141 
supplementary materials. 142 
Total protein extraction and protein expression assays– Total protein was extracted by mechanical 143 
homogenization from distal colon tissue in 1X RIPA buffer (Cell signaling 10X, 9806) containing 1:1000 144 
protease inhibitors at 4oC. Following 20 min incubation on ice, tissue homogenates were centrifuged at 145 
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14,000rpm for 10 minutes and the supernatant stored at -80oC for analysis. Total protein concentration 146 
was established using the Pierce BCA protein assay kit (23225) as compared to albumin standard. Furthe  147 
details of protein expression ELISA assays are available in the supplementary materials. 148 
Colonic lamina propria cell isolation – Single cell suspension from freshly harvested distal colon tissue 149 
was extracted with a lamina propria dissociation kit (Miltenyi Biotec, 130-097-410) on the gentleMACS 150 
dissociator as per instructions, incorporating chemical and physical dissociation.  151 
Flow cytometry & cell sorting - Nonspecific staining of cells was blocked by 20 minute incubation with 152 
anti-mouse CD16/CD32 Fc block (1:100 dilution) (BD Pharminogen, 553142). Macrophages and 153 
neutrophils were identified by cell surface expression of F4/80 and Ly6G using anti-mouse APC-F4/80 154 
(eBiosciences, 17-4801-82, clone BM8) and anti-mouse Pacific Blue-Ly6G (Biolegend, 127611) on 4% 155 
paraformaldehyde fixed cells using the BD FACSCanto II flow cytometer. Single stain pos tive and 156 
unstained negative cell controls were included. F4/80+ cells were collected using a FACSAria II (BD 157 
Biosciences) cell sorter. Data was analyzed using FlowJo software (Tree Star, Inc, Ashland, OR). 158 
Assessment of mucosal inflammatory cell phenotype, proliferation index and phosphorylated 159 
STAT-1 response– Immunohistochemistry was performed on 10% NBF fixed, paraffin embedded tissue 160 
sections of distal colon. Further details of immunohistochemistry protocols are available n the 161 
supplementary materials and methods. 162 
Macrophage culture protocols – Details of bone marrow derived and thioglycollate peritoneal 163 
macrophage culture protocols are available in the supplementary materials and methods. 164 
In vitro cell stimulation assay – Cells were stimulated with E. coli 0111:B4 derived LPS (Sigma, 165 
L4130) from 10mg/ml stock, or 5mM Adenosine 5’-triphosphate disodium sate hydrate (ATP) from 166 
90mM stock (Sigma, A22383-5G), stored at -20oC. Recombinant mouse IL -27 (NSO expressed, R&D 167 
systems, 2799-010/CF) was added to stimulation assay media as appropriate at 100ng/ml. Culture 168 
supernatant was collected and stored at -80oC for analysis. 169 
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Statistics - SigmaPlot 11.0 software was used for statistical analysis. Survival curves were analyzed 170 
according to the Kaplan-Meier estimator on GraphPad 6. Statistical differences wer  determined by 171 
ANOVA and non-parametric Rank Sum tests, with p values of ≤ 0.05 considered to represent a 172 
statistically significant difference between groups. If groups displayed normal variance, Student’s t-test 173 
was performed (as indicated in the figure legend text). Data is presented as mean +/- SEM.  174 
 175 
  176 
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Results 177 
IL-27 attenuates acute severe colitis in vivo 178 
Intra-rectal instillation of TNBS in SJL/J mice resulted in an acute severe left-sided colitis, with a 179 
rapid increase in disease activity index (DAI) within 24 hours. Mice treated with TNBS were included if 180 
their DAI was greater than 4 on day 1, reflecting appropriate response to TNBS. Mucosal delivery of LL-181 
IL -27 attenuated TNBS colitis with a decreased DAI and significantly less w ight loss from baseline 182 
starting weight, compared to L.lactis control (LL-C) (Figure 1a & 1b). LL-IL -27 was associated with a 183 
significantly lower colon weight and increased colon length (Figure 1c), resulting in a reduced colon 184 
weight:length ratio (p=0.005). 185 
Oral administration of LL-IL -27 is presumed to act locally since there was no evidence of 186 
systemic absorption, as determined by IL -27 p28 ELISA (Figure 1d). Although mucosally-delivered IL-187 
27 was not measurable systemically, we observed a decrease in serum C-reactive protein (CRP) i  LL-IL -188 
27 treated mice (Figure 1e). This can be attributed to indirect effects on liver production of CRP, possibly 189 
downstream of inflammatory cytokines such as IL-6, as will be discussed. 190 
LL-IL-27 resulted in a significant reduction in total histology colitis score compared to LL-C 191 
(Figure 2a & d), although this was surprisingly modest compared to clinical improvement. Assessment of 192 
the independent histological parameters of the composite score revealed significant protection against 193 
mucosal ulceration in those receiving LL-IL -27 (Figure 2b). We hypothesized that IL -27 may protect the 194 
epithelial barrier, shielding the innate immune system from contact with intesti al microbiota. IL -27 was 195 
previously shown to increase colonic epithelial cell proliferation, and to promote epithelial wound 196 
restitution in vitro 25. To explore this in vivo, we assessed epithelial cell proliferation by Ki67 197 
immunohistochemistry. Eliciting colitis increased epithelial proliferation by 50% but there was no effect 198 
on proliferation index associated with LL-I 27 (Figure 2c).  199 
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Our in vivo data shows that oral IL -27 attenuates acute severe colitis when administered shortly 200 
after the time of colonic insult. An important question is whether pre-exposure to IL -27 could impact 201 
disease induction as a prophylactic effect. Mice were pre-treated with LL-IL -27 for 2 weeks prior to intra-202 
rectal administration of TNBS. This did not affect acute colitis induction (Figure 3), suggesting that an 203 
active inflammatory microenvironment is required for IL -27 to suppress inflammation in the colonic 204 
mucosa.  205 
 206 
IL-27 reduces colonic neutrophil infiltrate associated with decreased CXC chemokine expression 207 
Previous studies have shown that lack of IL -27 signaling increased neutrophil influx to the site of 208 
acute bacterial infection in the peritoneal cavity 26 and lung 24. This raised the question of whether 209 
mucosal IL -27 might suppress neutrophil infiltration. To explore this as a potential mechanism, neutrophil 210 
and macrophage infiltration was assessed by myeloperoxidase (MPO) and F4/80 immunohistochemistry, 211 
respectively. Induction of acute TNBS colitis led to a precipitous increase in mucosal neutrophils 212 
(p=0.001) and a modest increase in macrophages (p<0.05). LL-IL -27 led to a significant reduction in 213 
MPO+ neutrophil infiltration into the colonic mucosa (Figure 4a & Supplementary Figure 1a). F4/80+ 214 
macrophage infiltrate did not alter with LL-I -27 treatment (Figure 4b & Supplementary Figure 1b).  215 
Neutrophils move to areas of acute inflammation via chemokine gradients, therefore xpression 216 
of several candidate chemokines in the distal colon was assessed. On day 2 post-TNBS instillation, 217 
CXCL1 and CXCL2 but not CXCL5 protein was significantly reduced in colitic mice treated with LL-IL -218 
27 compared to LL-C (Figure 4c). CXCL2, a potent neutrophil chemokine, was taken forward in further 219 
investigation and at the end of the treatment protocol (day 4 or time of death), the significant suppression 220 
persisted (Figure 4d).  221 
 222 
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Oral IL-27 reduces CXCL2 secretion in ex-vivo colon derived F4/80+macrophage  223 
Macrophages are major producers of chemokines that induce a neutrophil influx 27. The cellular 224 
source of CXCL2 in our acute TNBS colitis model was assessed by selecting F4/80+ cells from distal 225 
colon lamina propria cell suspension, on day 2 post-TNBS instillation, cultured fo  24 hours to assess 226 
CXCL2 response. These colitis derived F4/80+ macrophages secreted CXCL2, and this was significantly 227 
reduced in cells exposed to LL-I 27 in vivo (Figure 4e). 228 
 229 
IL-27 does not directly suppress macrophage CXCL2 expression ex vivo 230 
Having shown that IL-27 suppressed chemokine expression by colonic macrophages in vivo, we 231 
next evaluated whether this was a direct effect by examining IL-27 responses of different macrophage 232 
preparations. 233 
Bone marrow derived macrophage (BMDM) expressed IL -27Rα (Figure 5a) demonstrating their 234 
capability to respond to IL -27. LPS stimulation provoked robust CXCL2 secretion. However, addition of 235 
recombinant IL -27 (rIL -27) for the 5 hour duration of LPS stimulation did not suppress this response 236 
(Figure 5b). To investigate whether the macrophage chemokine response was suppressed by priming with 237 
IL -27 prior to LPS challenge, BMDM were cultured in media containing rIL -27 for 48 hours prior to LPS 238 
stimulation. Again, exposure to LPS led to CXCL2 secretion and this was not reduced by rIL -27 pre-239 
exposure (Figure 5c). 240 
To evaluate a different macrophage population, thioglycollate-induced peritoneal cells were 241 
examined, perhaps better representing the acute inflammatory macrophages in this in vivo colitis model. 242 
At day 4 post-thioglycollate injection, the majority of cells were F4/80+ macrophages, representing 243 
F4/80intermediate inflammatory and F4/80high resident macrophages, co-existing with Ly6G+ neutrophils 244 
(Figure 5d). Adherent cells were used as a macrophage enriched population, and expressed IL -27Rα. As 245 
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in BMDM, LPS induced robust CXCL2 expression and this was not altered by presence of rIL -27 (Figure 246 
5e). 247 
Overall, LPS induced CXCL2 protein expression in macrophages was not inhibited by rIL -27 in 248 
two independent in vitro cell culture models, suggesting this is not the direct mechanism for CXCL2 249 
suppression in vivo.  250 
However, it remained possible that macrophage responses would be site specific to the col n. To 251 
explore this, F4/80+ cells isolated from murine colon lamina propria were LPS stimulated for 24 hours, 252 
with or without rIL -27. As seen in the other macrophage culture models, LPS induced a striking increase 253 
in CXCL2 compared to unstimulated cells (Figure 5f). Once again, there was no significant IL -27 254 
suppression of CXCL2 production in response to LPS. This supports the hypothesis that mucosal delivery 255 
of IL -27 does not directly interfere with the ability of colonic lamina propria macrophages to secrete 256 
CXCL2 after an inflammatory stimulus.  257 
 258 
IL-27 suppression of acute severe colitis is T cell-independent 259 
Since IL -27 inhibits several T cell subsets, we assessed whether T cell mediated 260 
immunosuppression could be central to IL -27 effect in acute colitis.  261 
 TNBS colitis was evoked in Rag1-deficient (Rag1-/-) mice that lack mature T and B cells, and 262 
responses to LL-C or LL-IL -27 assessed. There was reduced disease severity evoked in the C57BL/6 263 
strain of mice due to relative resistance to TNBS (compared to SJL/J strain) 28. LL-IL -27 led to a 264 
significantly improved DAI (Figure 6a). LL-IL -27 treated mice lost significantly less weight initially, 265 
though the difference between the groups narrowed during the protocol with a strong trend for 266 
improvement in the LL-IL -27 treated group (Figure 6b). CXCL2 protein in distal colon homogenates was 267 
significantly inhibited by LL-IL -27 (Figure 6c), and there was a significant reduction in histological 268 
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colitis score (Figure 6d). Taken together, these data show that IL -27 mediated inhibition of acute colitis 269 
persists in Rag1-deficient mice, implying the mechanism is T cell-independent.  270 
 271 
IL-27 immunosuppression in acute severe colitis is IL-10-dependent  272 
It is known that IL -27 can induce the immunosuppressive cytokine, IL -10 29, 30 from Tr1 T 273 
regulatory cells 31, and other cell types, such as macrophages 17. Our previous data revealed that LL-IL -27 274 
evoked a significant colonic IL -10 response, from CD4+CD8α intra-epithelial T cells, and overall clinical 275 
improvement mediated by IL -27 was dependent on production of this cytokine in a chronic enterocolitis 276 
model 11. To evaluate whether IL -10 played a major role in the immunosuppressive function of IL -27 in 277 
the context of acute innate cell driven colitis, we employed an IL -10 deficient (C57BL/6 IL -10-/-) mouse 278 
model in our experimental colitis protocol. There was no significant difference in DAI (Figure 6e) or 279 
weight loss (Figure 6f) between mice treated with LL-C versus LL-IL -27. There was no reduction in 280 
CXCL2 (Figure 6g) nor total histology score (Figure 6h) associated with LL-IL -27. This suggests IL -27 281 
mediated immunosuppression in acute colitis is IL -10-dependent and CXCL2 reduction is downstream of 282 
this IL -10 dependency. 283 
 Next, IL -10 protein expression was assessed in distal colon homogenate on either day 2 (Figure 284 
6i) or day 4/time of death post-TNBS instillation (Figure 6j). On day 2, distal colonic IL -10 was increased 285 
by 25% in mice exposed to IL -27. Later in the treatment protocol there was no significant difference in 286 
mucosal IL -10 detected between colitic mice who received LL-C or LL-I -27. This suggests that early in 287 
disease pathogenesis, L.lactis delivered IL -27 hastens the immunoregulatory IL -10 response, increasing 288 
IL -10 in the colonic mucosal microenvironment, impacting clinical disease course and outcome. 289 
 290 
IL-27 induces phosphorylated STAT-1 in mucosal epithelial cells 291 
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To identify the cell type directly impacted by IL -27 treatment, immunohistochemistry was 292 
employed to identify STAT-1 phosphorylation in response to orally administered LL-IL -27. Multifocal 293 
mucosal epithelial cells and scattered inflammatory cells within the lamina propria and submucosa 294 
showed strong positive nuclear labeling for phosphorylated STAT 1 (Figure 7a). This suggests efficacy of 295 
LL-IL-27 is a consequence of both immune and non-immune cell mediated effects. In keeping with this, 296 
IL -27 was previously shown to promote epithelial wound restitution in vitro 25. As expected, gavage of 297 
LL-IL-27 in healthy non colitic mice did not result in STAT-1 phosphorylation response, again 298 
demonstrating that an inflammatory microenvironment is required for LL-IL -27 immunosuppression.  299 
 300 
IL-27 significantly reduces pro-inflammatory cytokine profile in vivo  301 
Gene expression of pro-inflammatory cytokines were assessed in distal colon homogenate, 302 
namely Il6, Il1β, Tnf, Il13, Il12, Ifng, Il17a, and Il22, along with the regulatory T cell associated 303 
transcription factor Foxp3. The majority of these genes were expressed at low abundance or undetectable 304 
and not investigated further. Il6, Il1β, and Tnf were significantly increased in all TNBS treated mice 305 
compared to ethanol controls (Figure 7b). Il6 expression was significantly lower in mice treated with LL-306 
IL -27 compared to LL-C. No differential expression of Il1β or Tnf was seen with LL-IL -27 treatment.  307 
In contrast, distal colon protein expression of IL6, IL1β and TNF were significantly reduced in 308 
colitic mice receiving LL-IL -27 treatment (Figure 7c), highlighting a discrepancy between gene and 309 
protein expression for the latter two cytokines. This suggests potential influences on translational or post-310 
translational regulation. Thus we hypothesized that IL -27 may inhibit the inflammasome as a mechanism 311 
of immunosuppression. However, there was no impact on expression of distal colon il-18 or 312 
inflammasome components (Nlrp3, Caspase-1 and Asc), nor LPS induced IL1β secretion from in vitro 313 
macrophage preparations (Supplementary Figure 2), suggesting IL-27 does not directly influence acute 314 
colonic inflammasome activation i vivo. 315 
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Discussion 317 
Our data show a novel immunosuppressive activity of the cytokine IL -27 in acute severe colitis, directed 318 
toward gut mucosal innate immune responses. Mucosal delivery of IL -27 reduced clinical parameters of 319 
colonic disease activity, repressed systemic inflammatory response, and improved colitis histology score. 320 
LL-IL-27 improved mucosal ulceration. This is important because mucosal healing is defined by the 321 
absence of ulcerated lesions in the gut mucosa during endoscopy, and this represents a primary endpoint 322 
in assessing effectiveness of IBD therapy.  323 
The mechanism of IL-27 directed immunosuppression was multifactorial. This data represents 324 
first in field evidence of IL-27 evoked reduction in colonic mucosal neutrophil infiltrate, associated with a 325 
decreased CXC chemokine gradient. This was T cell independent and IL -10 dependent, with early 326 
enhanced mucosal IL -10. IL -27 also significantly attenuated pro-inflammatory cytokine protein 327 
expression. Although there was no evidence of direct impact on epithelial cell proliferation, IL -27 328 
provoked an epithelial phosphorylated STAT-1 response. For the first time, we have revealed that IL-27 329 
attenuates acute immune responses in the colon in vivo in a non-infective, genetically intact host. 330 
IL -27 evoked reduction in myeloid cell infiltrate has been reported in different body sites, 331 
identified through genetic manipulation of IL -27 receptor signaling. Atherosclerotic prone Ldlr-/- mice 332 
had attenuated disease with hematopoietic cell IL -27Rα deficiency, mediated partly via reduced plaque 333 
chemokine gradient and infiltration of myeloid cells 32. Ebi3-/- mice demonstrated reduced granulocyte 334 
flux to acute peritonitis 26. When IL -27 receptor signaling was interrupted by genetic deficiency or 335 
antibody blocking, mice with systemic sepsis secondary to cecal puncture ligation and exposed to a 336 
secondary pneumonic bacterial insult, exhibited enhanced neutrophil infiltrate to the lungs This was 337 
associated with increased chemokine expression including CXCL2 and pro-inflammatory ediators such 338 
as IL-6, TNF, and IL1β 24. This IL -27 mediated blunting of granulocyte response was deleterious overall 339 
and associated with inability to resolve the secondary bacterial infection.  340 
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Neutrophils are necessary for efficient resolution of acute microbial attack through a variety of 341 
mechanisms 33. The suppression of neutrophil influx by IL-27 complicates IL -27 therapy for application 342 
to human disease. However, LL-IL -27 represents a localized rather than systemic therapy, delivered 343 
orally to act directly on the inflamed colonic mucosa, with no evidence of systemic IL -27 absorption as 344 
reported here and in our previous publication 11. The balance of beneficial to deleterious IL -27 inhibition 345 
of innate immunity appears site specific. Thus, IL -27 is beneficial in the circumstance of acute non-346 
infective colitis, by limiting granulocyte directed tissue damage, release of pro-inflammatory mediators 347 
and activation of downstream adaptive immune responses.  348 
CXCL2 is a potent neutrophil chemokine, secreted mainly by monocytes and macrophages, in 349 
response to LPS stimulation 27. There is existing evidence that IL -27 can modulate the functional capacity 350 
of macrophages and other innate cells. It is unclear whether IL -27 effects on innate cells are pro-351 
inflammatory or anti-inflammatory and it appears that the outcome is dependent on stimulus, cell type and 352 
surrounding or experimental microenvironment 14, akin to its pleiotropic effect on T cell biology. For 353 
example, IL -27 can enhance pro-inflammatory cytokine and chemokine expression from blood derived 354 
human monocytes cultured and stimulated in vitro 34,35. In the gut, host or recipient IL -27R knockout 355 
mice, with or without genetic silencing of TCR revealed a role of IL -27-induced, APC-derived, cytokine 356 
mediated Th17 responses in T cell driven colitis 36. Conversely, lung macrophages from IL-27Rα 357 
knockout mice exert enhanced pro-inflammatory cytokine and chemokine secretion, along with increased 358 
anti-microbial killing capacity 24 exemplifying a suppressive activity of IL -27 on innate immune cells. 359 
Iyer 17 revealed macrophage IL -10 secretion in response to LPS or type I interferons is dependent on 360 
endogenous IL -27 signaling. Therefore, it was reasonable to speculate that our orally delivered IL -27 may 361 
suppress the proinflammatory function of the colonic macrophage population. Indeed, our data suggest 362 
that colonic macrophages are a potent source of CXCL2 during acute colitis and his was blunted by in 363 
vivo exposure to IL -27. We did not find evidence to support a direct immunosuppressive effect of IL -27 364 
on macrophage chemokine response, despite utilizing three independent ex vivo macrophage culture 365 
models including colonic macrophages. 366 
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We then assessed the involvement of T cells in the IL -27-mediated immunosuppression in this 367 
acute colitis model. IL -27 inhibits Th2 and Th17 responses 13,14, although this was not likely to be 368 
prominent in our acute model given the rapid onset of pathology. T cells present in the normal colonic 369 
mucosa are part of the ‘physiological immunity’ that evokes tolerance to luminal antigens and appropriate 370 
response to pathogenic insult. IL -27 is known to promote T regulatory cell subsets 31, 37. However in our 371 
model, IL -27 immunosuppression of innate cell driven colonic pathology was T cell independent.  372 
We acknowledge that the direct cell target of orally delivered IL -27 in acute colitis remains 373 
elusive. We predict that IL-27 in acute severe colitis acts on epithelial cells and inflammatory cells of 374 
unknown phenotype. There are several immune cell types that may, independently or in conjunction, act 375 
in response to exogenous IL -27, such as neutrophils, dendritic cells or innate lymphoid cells and although 376 
outside the scope of this current study, warrants further investigation to reveal novel biological functions 377 
of IL-27. Neutrophils can secrete chemokines and attract an increasing neutrophil influx 38. IL -27 can 378 
inhibit neutrophil ROS production 16, 19, reduce their expression of the surface integrin Mac-1 16, 19 and 379 
provoke short lived IL1β secretion either independently 16 or in response to bacterial challenge 19, 24. IL-27 380 
receptor deficiency led to enhanced neutrophil intracellular bacterial killing 24. Neither neutrophil survival 381 
nor apoptosis is known to be affected by IL -27 16. Another potential cell candidate is dendritic cells 382 
(DCs). Human immature DCs exposed to IL -27 displayed reduced antigen presenting capacity 22. IL -27 383 
provokes DC derived IL -10, and suppresses downstream Th1 and Th17 response 20, 21. This mechanism 384 
impacts disease outcome in CNS autoimmune pathology, with vaccination of IL -27 primed DCs 385 
attenuating murine EAE 21. Another potential cell candidate is colonic epithelial cells, as this cell 386 
compartment can secrete chemokines 39, 40 and our results indicate that these cells strongly express 387 
phosphorylated STAT1 in response to mucosally delivered LL-IL -27 in vivo.  388 
This data confirms the potential for oral L. lactis IL -27 to be a potential rescue medical therapy in 389 
acute severe colitis. Lactococcus lactis is a non-pathogenic, non-colonizing and non-transmissible food 390 
grade bacterium. The use of this bacteria as a mucosal delivery system for therapeutic proteins and 391 
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vaccines has been reviewed elsewhere 41-43. We showed previously that orally delivered IL -27 attenuates 392 
chronic T cell derived colonic inflammation 11 and now present novel evidence to show efficacy towards 393 
acute innate cell derived colonic pathology, highlighting translational impact as a new or adjunct medical 394 
treatment strategy in acute severe colitis. 395 
  396 
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Figure Legends 516 
Figure 1. Oral delivery of IL-27 suppresses acute severe colitis. (a) LL-IL-27 evokes a decreased 517 
disease activity index (DAI) compared to LL-C; 5.8 vs. 8.2 on day 1, 5.3 vs. 8.9 on day 2 and 4.1 vs. 8.2, 518 
on day 3, maximum 12, *p=0.001. (b) LL-IL -27 led to significantly less weight loss than TNBS+LL-C or 519 
TNBS alone, p<0.01 and p<0.05 on days 2 and 3, respectively. Data in (a) a d (b) combined from 3 520 
separate experiments. n= 14, 21, 25, 25 for ethanol, TNBS, TNBS+LL-C and TNBS+LL-IL-27 groups, 521 
respectively. (c) Macroscopic colitis score represented by colon weight (mg) and length (cm). Colitis 522 
renders the colon shorter and heavier. Both parameters improved with LL-IL -27 vs. LL-C; colon length, 523 
p=0.001 and colon weight, p=0.017. Data combined from 2 separate experiments. n= 7, 16, 18, 19 for 524 
ethanol, TNBS, TNBS+LL-C and TNBS+LL-IL-27, respectively. (d) SJL/J colitic mice (2mg TNBS) 525 
receiving daily gavage of LL-IL27 for 4 days (n=10) showed serum IL-27 of 2.9pg/ml, indistinguishable 526 
from non-colitic untreated mice (n=8, 4.1 pg/ml), p=0.469 (t-test). (e) IL-27 provoked an improved 527 
systemic inflammatory response measured by serum CRP (day 2); LL-C vs. LL-IL -27, p=0.019 (t-test). 528 
Data from one experiment. n=5, 3, 10, 9, 10 for untreated, ethanol, TNBS, TNBS+LL-C and TNBS+LL-529 
IL -27, respectively. All data (a-e) presented as mean+SEM. 530 
Figure 2. Oral delivery of IL-27 leads to improved histological colitis score and protection against 531 
ulceration in acute severe colitis. (a) Cumulative histological colitis score based on 5 parameters 532 
(degree of inflammatory cell infiltrate/ mucosal ulceration/ crypt hyperplasia/ goblet cell depletion, 533 
presence of granuloma) with a maximum of 14. TNBS+LL-C vs. TNBS+ LL-IL -27, p=0.035. (b) Degree 534 
of distal colonic mucosa ulceration score, graded on a scale of 0-4. 0=none, 1=erosion, 2=mild ulceration, 535 
3=moderate ulceration, 4=severe ulceration. TNBS+LL-C vs. TNBS+ LL-IL -27, p=0.008. Data generated 536 
from randomly selected animals from 2 experiments. n=5,5,6,7 for ethanol, TNBS, TNBS+LL-C and 537 
TNBS+LL-IL27, respectively. Mean + SEM. (c) Epithelial proliferation index was assessed by Ki67 538 
immunohistochemistry on paraffin embedded distal colon sections. n=5/group from 2 experiments. Ind x 539 
derived from number of Ki67 positive cells/total number epithelial cells/ HPF, expressed as percentage. 540 
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Mean + SEM % from 5 HPF per sample used in analysis. Colitis evoked a significant increase in 541 
proliferation index across all groups compared to ethanol control; p=0.009, 0.001 & 0.002 for TNBS 542 
alone, +LL-C and +LL-IL -27, respectively. There was no significant difference between TNBS alone vs. 543 
+LL-C vs. +LL-IL -27 (p=0.243), t-test. (d) Representative distal colon photomicrographs of each 544 
experimental group. There is full-thickness necrosis of the mucosa and marked submucosal inflammation 545 
and edema in both the TNBS alone and TNBS+LL-C treated mice. LL-IL -27 treatment significantly 546 
reduced mucosal necrosis and decreased inflammatory infiltrates. Slides were optically scanned with an 547 
Aperio AT2 digital slide scanner. Hematoxylin and eosin staining. 548 
Figure 3. An active inflammatory microenvironment is required for oral IL-27 to suppress 549 
inflammation in the colonic mucosa. Pre-exposure to LL-IL -27 (10 oral gavages over 2 week period) 550 
prior to intra-rectal instillation of 2mg TNBS (SJL/J 6-8 week old male mice) did not impact acute colitis 551 
induction as measured by (a) disease activity index, (b) weight loss from starting weight, or (c) 552 
macroscopic colitis score (colon length and weight). Data presented combined from 2 separate 553 
experiments, n=10/group, as mean + SEM; ANOVA on Ranks & Rank Sum test for pairwise 554 
comparisons. 555 
 556 
Figure 4. Oral IL-27 reduces colonic neutrophil infiltrate associated with decreased CXC 557 
chemokine expression. Distal colon inflammatory cell phenotype assessed by immunohistochemistry 558 
using (a) myeloperoxidase (MPO) and (b) F4/80 positivity to identify neutrophils and macrophages, 559 
respectively. Data generated from randomly selected animals from 2 experiments. n=5,5,6,6,8 for 560 
untreated, ethanol, TNBS, TNBS+LL-C and TNBS+LL-IL-27, respectively. Mean + SEM. (a) Treatment 561 
with IL-27 led to a significant reduction in MPO+ neutrophil infiltration into the colonic mucosa 562 
(p=0.002, t-test). (b) F4/80+ macrophage infiltrate did not alter with LL-I 27 treatment (p=0.250, t-test). 563 
(c) On day 2 post TNBS instillation, CXCL1 and CXCL2 but not CXCL5 protein (measured by ELISA 564 
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and normalized to mg total protein concentration) were significantly reduced in distal colon homogenate 565 
in colitic mice treated with LL-IL -27 compared to LL-C (p=0.026, p=0.038 & p=0.427 (t-test), 566 
respectively). Data represents mean + SEM, generated from 2 separate experiments, n=10 /group. (d) 567 
This IL-27 associated reduction in CXCL2 expression persisted as measured later in th  experimental 568 
protocol (day 4 or time of death), p=0.001 and p=0.003, compared to TNBS plus LL-C and TNBS alone, 569 
respectively. Mean + SEM, generated from one experiment, n=3, 3, 8, 8, 11 for untreated, ethanol, TNBS, 570 
TNBS+LL-C and TNBS+LL-IL27, respectively. (e) Ex-vivo derived colitis associated lamina propria 571 
F4/80+ macrophage cells secreted CXCL2 measured by ELISA after 24 hours culture at 37oC (105 572 
cells/200µl), and this was significantly reduced in cells exposed in vivo to LL-IL -27, p=0.001 (t-test). 573 
Data generated from 5 pooled distal colon samples per group. 574 
 575 
Figure 5. IL-27 does not directly suppress macrophage CXCL2 expression. To investigate the 576 
mechanism of IL-27 mediated immunosuppression, chemokine response in bone marrow derived 577 
macrophage (BMDM) (a-c), thioglycollate induced peritoneal macrophage (TPM) (d & e) and colonic 578 
lamina propria F4/80+ macrophage (f) were assessed. (a) >90% of M-CSF cultured bone marrow derived 579 
cells expressed F4/80 and IL-27Rα. (b) BMDM were stimulated for 5 hours with various concentrations 580 
of LPS as labelled +/- rIL27 (100ng/ml) and CXCL2 measured in supernatant by ELISA. Combined data 581 
from several experiments, generated from >3 wells/experimental condition. LPS resulted in a robust 582 
CXCL2 response but there was no differential response in association with IL-27, t-test. (c) Exposure for 583 
>48 hours prior to LPS stimulation did not impact CXCL2 response, t-test. (d) Peritoneal cell phenotype 584 
day 4 post IP thioglycollate injection. Cells expressed IL-27Rα. (e) Adherent cells were stimulated with 585 
50ng/ml of LPS +/- 100ng/ml rIL27, for 5 or 72 hours. Again, LPS resulted in a robust CXCL2 response 586 
but there was no differential response in association with IL-27. (f) This was also seen in ex vivo colonic 587 
lamina propria F4/80+ cells stimulated for 24 hours with 50ng/ml of LPS +/- 100ng/ml rIL27, t-test. 588 
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Results in C, E & F presented from one experiment, with the same pattern of expression seen in repeat 589 
experiment. All data presented as mean + SEM. 590 
 591 
Figure 6. IL-27 immunosuppression in acute TNBS colitis is T cell-independent and IL-10-592 
dependent, evoking early IL-10 secretion in the colonic mucosa. (a-d) 4mg TNBS instilled intra-593 
rectally into Rag-/- mice. Data combined from 2 separate experiments. n=10/group. There was a 594 
significant difference in (a) DAI in mice treated with LL-IL -27 compared to LL-C on day 1 and 2, 595 
p=0.013 & p=0.040 respectively, t-test, and (b) degree of weight loss from baseline on day 1 (p=0.019), 596 
then a trend just under significance on days 2&3 (p=0.06), t-test. (c) Distal colon homogenate CXCL2 597 
protein was significantly reduced with LL-I -27, p=0.028, (d) as was distal colon histology score, 598 
p=0.028, t-test. (e-h) 6mg TNBS instilled intra-rectally into IL-10-/- mice. Data combined from 2 separate 599 
experiments. n=8/group. (e) DAI, p=0.237, 0.903, 0.681, respectively on day 1, 2 & 3, LL-I -27 vs. LL-600 
C, t-test, (f) weight loss from baseline, p=0.727, 0.751, 0.716, respectively on day 1, 2 and 3, LL-IL -27 601 
vs. LL-C, t-test. (g) CXCL2 protein in distal colon homogenate, p=0.959 and (h) distal colon histology 602 
score, p=0.608, t-test, were not significantly different in mice treated with LL-IL -27 compared to LL-C. 603 
(i) On day 2 post TNBS instillation in SJL/J mice, there was a significant increase in distal colon IL-10 604 
protein associated with IL-27, p=0.01, t-test. (j) Later in the treatment protocol, at day 4 or time of death, 605 
this difference in IL-10 protein expression was not apparent, p=0.653. At both time points, n=10/group, 606 
combined data from 2 experiments.  607 
 608 
Figure 7. IL-27 is associated with phosphorylated STAT-1 in colonic epithelial cells and 609 
significantly reduces pro-inflammatory cytokine profile in vivo. (a) Immunohistochemistry for 610 
phosphorylated STAT-1 (Tyr701). Multifocal mucosal epithelial cells and scattered inflammatory cells 611 
within the lamina propria and submucosa show strong positive nuclear labeling for phosphorylated 612 
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STAT-1 in response to oral LL-IL -27. Occasional cells show both strong nuclear and variable 613 
cytoplasmic labeling. There is no phosphorylated STAT-1 immunopositivity in colitic m ce who received 614 
no treatment or treatment with LL-C. Diaminobenzidine chromogen and hematoxylin counterstai . This 615 
pattern of expression was seen in all mice per group (n=3). (b) Cytokine gene expression profile n distal 616 
colon homogenate was assessed by Taqman RT-PCR assays (Applied Biosystems) and analyzed with 617 
ddCt method of relative quantification; normalization to endogenous GAPDH control and level of 618 
expression compared to ethanol control group. Data, combined from 2 experiments, presented as mean + 619 
SEM. Il6 (p=0.003), Il1b (p=0.001) and Tnf (p=<0.01) were significantly increased in TNBS treated mice. 620 
Expression of Il6 was significantly reduced with LL-IL -27 compared to LL-C (p=0.036), whereas no such 621 
effect was seen for Il1b and Tnf. n=7, 10-13, 10-15, 10-15, for ethanol, TNBS alone, TNBS+LL-C and 622 
TNBS+LL-IL-27, respectively. (c) Cytokine protein expression in distal colon homogenate measured by 623 
ELISA and normalized to mg total protein. Combined data presented from 2 experiments as mean + 624 
SEM. n=5, 8-10, 7-10, 10, for ethanol, TNBS alone, TNBS+LL-C and TNBS+LL-IL-27, respectively. 625 
Protein expression of IL-6 (p=0.002), IL-1β (p=0.003) and TNF (p=0.031) were significantly reduced in 626 
the distal colon of colitic mice receiving LL-I -27 treatment compared to LL-C.  627 
 628 
 629 
Supplementary Figure Legends_McLean et al_ Interleukin 27 is a potential rescue therapy for acute 
severe colitis via interleukin-10 dependent, T cell independent attenuation of colonic mucosal innate 
immune responses 
 
Supplementary Figure 1 show representative distal colon photomicrographs of F4/80+ and MPO+ 
macrophages and neutrophils, respectively in each experimental group as labeled. This was determined by 
immunohistochemistry with positive staining shown as brown colour on counterstained formalin fixed 
paraffin embedded tissue sections. TNBS precipitated an increase in macrophages and neutrophils. Colitic 
mice treated with LL-IL27 had a significantly reduced colonic mucosal neutrophil infiltrate compared to 
those treated with LL-C (p=0.002, t-test). Slides were optically scanned with an Aperio AT2 digital slide 
scanner.  
 
Supplementary Figure 2. IL-27 does not directly influence acute colonic inflammasome activation in 
vivo. There was no evidence of IL-27 mediated suppression of the NLRP3 inflammasome (il18, Asc, Nflp3, 
Caspase-1) in distal colon homogenate, assessed by Taqman RT-PCR gene expression assays (Applied 
Biosystems) and analyzed with ddCt method of relative quantification; normalization to endogenous 
GAPDH control and level of expression compared to ethanol control group (a & b). n=10/group, t-test. 
Bone marrow derived macrophage (BMDM) (c and thioglycollate-induced peritoneal macrophage (TPM) 
(d) were stimulated for 5 hours or 72 hours with various concentrations of LPS as labeled, +/- 5mM ATP, 
+/- rL27 (100ng/ml). IL -1β was measured in supernatant by ELISA. (c) Combined data from several 
experiments, generated from >2 wells/experimental condition. (d) Data presented from one experiment, 
with the same pattern of expression seen in repeat experiment. LPS plus ATP resulted in a robust IL-1β 
response but there was no differential response in association with IL-27 in either macrophage population. 
Mean + SEM. BMDM 100ng LPS dose data passed normality test and analyzed by t-test, all others Rank 
Sum test. 
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